Mi Ju Son

Dr. Mi Ju Son

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2014 in BMJ Open
Verified
Journal Article
Open access
PDF file
JLJu Ah Lee
Ju Ah Lee
MSMi Ju Son
Mi Ju Son
JCJiae Choi
Jiae Choi
JJJi Hee Jun
Ji Hee Jun
JKJong-In Kim
Jong-In Kim
Myeong Soo LeeMyeong Soo Lee
Myeong Soo Lee
Objective To assess the clinical evidence for bee venom acupuncture (BVA) for rheumatoid arthritis (RA). Design Systematic review of randomised controlled trials (RCTs). Setting We searched 14 databases up to March 2014 without a language restriction. Participants Patients with RA. Intervention BVA involved injecting purified, diluted BV into acupoints. We included trials on BVA used alone or in combination with a conventional therapy versus the conventional therapy alone. Primary outcomes Morning stiffness, pain and joint swelling Secondary outcomes Erythrocyte sedimentation rate (ESR), C reactive protein (CRP), rheumatoid factor, the number of joints affected by RA and adverse effects likely related to RA. Results A total of 304 potentially relevant studies were identified; only one RCT met our inclusion criteria. Compared with placebo, BVA may more effectively improve joint pain, swollen joint counts, tender joint counts, ESR and CRP but was not shown to improve morning stiffness. Conclusions There is low-quality evidence, based on one trial, that BVA can significantly reduce pain, morning stiffness, tender joint counts, swollen joint counts and improve the quality of life of patients with RA compared with placebo (normal saline injection) control. However, the number of trials, their quality and the total sample size were too low to draw firm conclusions. Trial registration number PROSPERO 2013: CRD42013005853.

23 April 2014 in BMJ Open
Verified
Journal Article
Open access
PDF file
JLJu Ah Lee
Ju Ah Lee
MSMi Ju Son
Mi Ju Son
JCJiae Choi
Jiae Choi
KYKyung-Jin Yun
Kyung-Jin Yun
JJJi Hee Jun
Ji Hee Jun
Myeong Soo LeeMyeong Soo Lee
Myeong Soo Lee
Introduction This systematic review aims to analyse the trial data on the effects of bee venom acupuncture (BVA) for rheumatoid arthritis (RA). Methods and analysis The following 14 databases will be searched from their inception to March 2014: MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), AMED, CINAHL, six Korean medical databases (OASIS, Korean Traditional Knowledge Portal, Korean Studies Information Service System, KoreaMed, Korean Medical Database and DBPIA) and three Chinese databases including CNKI (China National Knowledge Infrastructure), Wanfang and VIP. The methodological quality will be assessed using the Cochrane risk of bias tool. Dissemination The systematic review will be published in a peer-reviewed journal. The review will also be disseminated electronically and in print. Trial registration number PROSPERO 2013: CRD42013005853

1 December 2017 in Complementary Therapies in Medicine
Verified
Journal Article
Open access
MSMi Ju Son
Mi Ju Son
YKYoung-Eun Kim
Young-Eun Kim
YSYoung Il Song
Young Il Song
YKYun Hee Kim
Yun Hee Kim
This systematic review aimed to assess the clinical evidence for the widespread use of herbal medicines in treating acute otitis media. Eleven electronic databases, including MEDLINE, EMBASE, and the CENTRAL were searched, without language limitations. All randomised controlled trials involving the use of herbal medicines, alone or in combination with conventional therapies, for acute otitis media were included. We identified 4956 studies, of which seven randomised clinical trials met the inclusion criteria. The overall risk of bias of the included trials was relatively high or unclear. Treatment with Longdan-xiegan decoction or Shenling-baizhu powder, combined with antibiotics, appeared to be more effective than treatment with antibiotics alone in terms of the proportion of patients with total symptom recovery. Moreover, combination treatment of Sinupret® and antibiotics facilitated the recovery of middle ear conditions and hearing acuity. Despite some indications of potential symptom improvement, the evidence regarding the effectiveness and efficacy of herbal medicine for acute otitis media is inconclusive due to the poor quality of trials included. Moreover, we only analysed seven trials in this review. Therefore, to properly evaluate the effectiveness of herbal medicine for acute otitis media, systematic reviews based on more rigorously designed randomized trials are warranted in the future.

10 June 2022 in Medicine
Verified
Journal Article
Open access
MKMi Mi Ko
Mi Mi Ko
BKBo-Young Kim
Bo-Young Kim
MSMi Ju Son
Mi Ju Son
KJKyung Hwan Jegal
Kyung Hwan Jegal
WCWon Seok Chung
Won Seok Chung
SKSungha Kim
Sungha Kim
Introduction: In South Korea, the prevalence of obesity has continuously increased over the last decade, and the burden of social and economic costs has also increased immensely. The purpose of this study is to investigate the clinical characteristics and current status of patients receiving herbal medicine (HM) treatment for weight loss in Korean medicine (KM) by constructing a multi-institutional prospective registry. Methods and analysis: This is a prospective, observational, multi-center registry, including patients visiting the KM clinics in South Korea for weight loss. This study will collaborate with 15 KM clinics and recruit patients into the registry between October 2021 and October 2022. The study population will include patients visiting the KM clinics for weight loss. A total of 1000 eligible patients visiting the KM clinics for weight loss who decide to undergo HM treatment will be enrolled in the registry. After enrollment, we will collect the individual characteristics of each patient, such as body mass index, body composition test, liver and kidney function tests, and information on prescribed HM. We will also record the adverse events at each visit. Discussion: This study is the first prospective, multicenter registry of HM for weight loss in KM clinics. The results of this registry may show the current status of patients who receive HM treatments for weight loss and provide evidence for reasonable decision-making on KM healthcare policy for obese patients in the future.

1 January 2019 in Medicine
Verified
Journal Article
Open access
MJMi-Kyung Jeong
Mi-Kyung Jeong
YKYoung-Eun Kim
Young-Eun Kim
AKAnna Kim
Anna Kim
JJJeeyoun Jung
Jeeyoun Jung
MSMi Ju Son
Mi Ju Son
Introduction: Bu-Zhong-Yi-Qi-Tang (BZYQT) is an herbal drug that is widely used to treat various diseases, including gastrointestinal diseases, allergic rhinitis, and atopic dermatitis (AD) in East Asian countries. BZYQT has been shown to have anti-allergic, anti-inflammatory, and immunoregulatory properties in experimental studies, and there is substantial clinical evidence of its effect on AD. This review will systematically assess the evidence of BZYQT for the treatment of AD. Methods/design: Eleven databases will be searched from their inception without language restriction. Randomized controlled trials that examined BZYQT or modified BZYQT for AD will be included. The selection of the studies, data abstraction, and validations will be performed independently by 2 researchers. The methodological qualities of the randomized controlled trials will be assessed using the Cochrane Collaboration tool for assessing the risk of bias. Ethics and dissemination: This systematic review will be published in a peer-reviewed journal and will also be disseminated electronically or in print. It will be useful to inform and guide healthcare practitioners. Trial register number: CRD42018105173.

1 July 2019 in Medicine
Verified
Journal Article
Open access
MSMi Ju Son
Mi Ju Son
GYGeum-Jin Yang
Geum-Jin Yang
EJEun-Heui Jo
Eun-Heui Jo
YSYu-Hwa Shim
Yu-Hwa Shim
SKSu-Jin Kang
Su-Jin Kang
MPMin Cheol Park
Min Cheol Park
Introduction: Several studies have found that obesity is associated with atopic dermatitis (AD); however, the mechanisms underlying the association are largely unknown. This study aims to assess the association of AD with obesity in the Korean population and verify its mechanism via a multi-omics analysis. Methods and analysis: A case–control study will be conducted in the Republic of Korea. A total of 80 subjects, aged 4 to 12 years, matched for age and sex, with body mass index at or above the 85th percentile or at or below the 25th percentile, will be included. Subjects will be assigned to the following 4 groups: obese/overweight with AD, normal/underweight with AD, obese/overweight control, and normal/underweight control. Serum metabolome and immune biomarkers, as well as fecal metabolome and microbiome biomarkers, will be analyzed. Serum eosinophil cationic protein, total serum Immunoglobulin E (IgE), and specific IgE will be analyzed to assess allergic tendency. The SCORing of AD index, the children's dermatology life quality index, body composition analysis, and the Korean gastrointestinal symptom rating scale will be obtained to assess the disease status and severity of the subjects. Discussion: The findings of this study are expected to provide evidence of an association between AD and obesity via a gut microbiome-metabolome-immune mechanism. Therefore, it may improve future management strategies for AD. Trial registration: This study has been registered at the Korean National Clinical Trial Registry, Clinical Research Information Service (KCT0003630).